Research readouts, treatment and access decisions, and community updates for people living with sickle cell disease and the people who care for them — each one dated, with a link to the original source where there is one.
31 articles match your filtersFree, no login required
Looking for earlier coverage? Browse the news archive.
The global Sickle Cell Anemia Testing and Screening Market is expected to experience significant growth over the next decade as healthcare systems worldwide strengthen early…
The Clinical, Medical and Regulatory (CMR) department at Novo Nordisk is one of the most diverse and collaborative groups within the organization. From healthcare provider…
Key Points Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo…
A new large-scale systematic review and modelling analysis has estimated that more than 8.8 million children and adolescents in sub-Saharan Africa were living with sickle cell…
The Sickle Cell Anemia Testing and Screening Market offers growth opportunities through expanded newborn testing, molecular diagnostics, and digital workflows. Companies must…
Building on its commitment to make insurance more accessible, especially for those affected by chronic or rare diseases, the insurer BNP Paribas Cardif is introducing new pricing…
Sickle Cell Disease is included as an EHA 2026 disease-area keyword under non-malignant hematology, with relevant subtypes including Sickle Cell Pain Crises, Vaso-Occlusive…
Fulcrum Therapeutics said it is discontinuing development of pociredir, its experimental oral treatment for sickle cell disease (SCD), after the U.S. Food and Drug Administration…
Fulcrum Therapeutics has begun a strategic review that may result in it getting sold, a move made after the company’s main medicine hit a possibly insurmountable obstacle. On…
Fulcrum Therapeutics said today it is scrapping its lead pipeline program to develop pociredir as a treatment for sickle cell disease (SCD) and launching a “comprehensive” review…
June 2 (Reuters) - Shares of Fulcrum Therapeutics (FULC.O) , opens new tab plunged 52% on Tuesday after the company said it would abandon development of its experimental…
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206 SHANGHAI , June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. ( Correctseq ), a…
